CSL Limited Announces Cessation of Securities Due to Unmet Conditions
CSL Limited has announced the cessation of 50,194 securities due to unmet conditional rights, impacting its capital structure and stakeholders. The latest analyst rating for CSL stock (AU:CSL) is a Buy with a price target of A$225.00. CSL operates in the biotechnology sector, focusing on innovative medicines and therapies, with a current market cap of A$86.86B and an average trading volume of 1,361,230.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from CSL ( (AU:CSL) ).
CSL Limited announced the cessation of 50,194 securities due to the lapse of conditional rights, as the conditions were not met or became unachievable. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting the challenges in meeting certain operational conditions.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and provision of innovative medicines and therapies. The company is known for its work in the areas of vaccines, blood plasma derivatives, and other biopharmaceutical products, serving a global market.
Average Trading Volume: 1,361,230
Technical Sentiment Signal: Sell
Current Market Cap: A$86.86B
See more insights into CSL stock on TipRanks’ Stock Analysis page.
